Linvoseltamab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A human, immunoglobulin G4 (IgG4) bispecific antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, linvoseltamab targets and binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and BCMA on BCMA-expressing tumor cells. This activates and redirects CTLs to BCMA-expressing tumor cells, leading to CTL-mediated killing of BCMA-expressing tumor cells. BCMA, a member of the tumor necrosis factor receptor superfamily that is specifically overexpressed on malignant plasma cells, plays a key role in promoting plasma cell survival.

**Synonyms:** - Anti-BCMA x Anti-CD3 Bispecific Antibody REGN5458 - Anti-BCMA/CD3 Bispecific Antibody REGN5458 - BCMA x CD3 Bispecific Antibody REGN5458 - LINVOSELTAMAB - Linvoseltamab-gcpt - Lynozyfic - Lynozyfic - REGN 5458 - REGN-5458 - REGN5458